leisure time -WSS

leisure time

author：leisure time 2025-10-03 01:03:37 - browse：72

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

hotspot

WSS

Military medical care influenced by rank and race, new study finds

Big Tobacco's 'harm reduction': Is it for real, or a sham?

'Screen and refer' systems are hurting patients

Crowdfunding for unproven stem cell procedures spreads misinformation

AstraZeneca lung cancer study comes in below expectations

With measles on the rise, a personal story of a devastating disease

knowledge

leisure time

entertainment

In age of alternative facts, a scholarly course on calling out crap

HIV vaccine remains elusive. Immunologists keep trying new ideas

Supreme Court strikes down use of affirmative action

Drug cartel violence flares in western Mexico after vigilante leader's killing

Tori Bowie and the unacceptable rates of Black maternal death

Lupron, used to halt puberty in children, may cause lasting health problems

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Undocumented workers face uncertainty as immigration law takes effect in Florida

Bright Health sells Medicare Advantage business to Molina

The wait for US passports is creating travel purgatory and snarling summer plans

focus

Venture capitalist Bob Kocher on the state of digital health

Dexcom's push to bring CGM to type 2 diabetes patients

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Solving academic medical centers' existential crisis

Addiction experts warn against a second 'war on drugs'

hotspot

leisure time

leisure time

knowledge